Form 8-K - Current report:
SEC Accession No. 0001437749-25-021445
Filing Date
2025-06-27
Accepted
2025-06-27 17:00:25
Documents
14
Period of Report
2025-06-27
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20250627_8k.htm   iXBRL 8-K 25264
6 mbrx20250627_8kimg001.jpg GRAPHIC 3372
  Complete submission text file 0001437749-25-021445.txt   164682

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20250627.xsd EX-101.SCH 3579
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20250627_def.xml EX-101.DEF 11424
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20250627_lab.xml EX-101.LAB 15310
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20250627_pre.xml EX-101.PRE 11584
16 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20250627_8k_htm.xml XML 2846
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 251087444
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)